@DellTech: AI is transforming drug discovery, enabling faster breakthroughs that can lead to better patient outcomes. Dell AI Fact…
Summary
Dell Technologies highlights how AI is accelerating drug discovery and improving patient outcomes through their AI Factory partnership with NVIDIA, offering tailored solutions for enterprise adoption.
Similar Articles
AI is accelerating drug development
AI is transforming U.S. pharmaceutical R&D by accelerating drug discovery, preclinical testing, clinical trials, and regulatory review, with early evidence suggesting it could cut development times by roughly half and reduce costs.
@FinanceYF5: Is AI Really Accelerating Drug Development? According to McKinsey's latest research, some early signs have emerged: The…
McKinsey's latest research indicates that AI is accelerating drug development, with candidate drugs utilizing AI to shorten the discovery phase by 15% to 80%.
Article: 'Artificial intelligence in drug discovery — what it is, where we stand and the path forward'
A Nature Reviews Drug Discovery perspective critically reviews AI in drug discovery, noting limited clinical impact and offering recommendations for improving translational relevance.
Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
Bristol Myers Squibb is deploying its second NVIDIA DGX SuperPOD based on DGX Vera Rubin NVL72 systems, creating the most powerful AI cluster in life sciences to accelerate drug discovery and make AI accessible to all scientists.
AI in drug discovery — what it is, where we stand and the path forward
This article provides an overview of AI in drug discovery, discussing its current applications and future directions.